173 related articles for article (PubMed ID: 8402613)
1. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system.
Slawin K; Kadmon D; Park SH; Scardino PT; Anzano M; Sporn MB; Thompson TC
Cancer Res; 1993 Oct; 53(19):4461-5. PubMed ID: 8402613
[TBL] [Abstract][Full Text] [Related]
2. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
Greenwald P
J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
[TBL] [Abstract][Full Text] [Related]
3. Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats.
McCormick DL; Rao KV; Dooley L; Steele VE; Lubet RA; Kelloff GJ; Bosland MC
Cancer Res; 1998 Aug; 58(15):3282-8. PubMed ID: 9699656
[TBL] [Abstract][Full Text] [Related]
4. Experimental oncogene induced prostate cancer.
Thompson TC; Kadmon D; Timme TL; Merz VW; Egawa S; Krebs T; Scardino PT; Park SH
Cancer Surv; 1991; 11():55-71. PubMed ID: 1726789
[TBL] [Abstract][Full Text] [Related]
5. Cholecalciferol (vitamin D3) and the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) are synergistic for chemoprevention of prostate cancer.
Tokar EJ; Ancrile BB; Ablin RJ; Webber MM
J Exp Ther Oncol; 2006; 5(4):323-33. PubMed ID: 17024972
[TBL] [Abstract][Full Text] [Related]
6. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.
Costa A; Formelli F; Chiesa F; Decensi A; De Palo G; Veronesi U
Cancer Res; 1994 Apr; 54(7 Suppl):2032s-2037s. PubMed ID: 8137334
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO.
Moon RC; Kelloff GJ; Detrisac CJ; Steele VE; Thomas CF; Sigman CC
Anticancer Res; 1994; 14(1A):5-11. PubMed ID: 8166455
[TBL] [Abstract][Full Text] [Related]
8. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide.
Pienta KJ; Nguyen NM; Lehr JE
Cancer Res; 1993 Jan; 53(2):224-6. PubMed ID: 7678070
[TBL] [Abstract][Full Text] [Related]
9. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide.
Pollard M; Luckert PH; Sporn MB
Cancer Res; 1991 Jul; 51(13):3610-1. PubMed ID: 1829024
[TBL] [Abstract][Full Text] [Related]
10. A model to study c-myc and v-H-ras induced prostate cancer progression in the Copenhagen rat.
Lehr JE; Pienta KJ; Yamazaki K; Pilat MJ
Cell Mol Biol (Noisy-le-grand); 1998 Sep; 44(6):949-59. PubMed ID: 9763199
[TBL] [Abstract][Full Text] [Related]
11. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
Raina K; Blouin MJ; Singh RP; Majeed N; Deep G; Varghese L; Glodé LM; Greenberg NM; Hwang D; Cohen P; Pollak MN; Agarwal R
Cancer Res; 2007 Nov; 67(22):11083-91. PubMed ID: 18006855
[TBL] [Abstract][Full Text] [Related]
12. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model.
Raghow S; Kuliyev E; Steakley M; Greenberg N; Steiner MS
Cancer Res; 2000 Aug; 60(15):4093-7. PubMed ID: 10945615
[TBL] [Abstract][Full Text] [Related]
13. N-(4-hydroxyphenyl)retinamide prevents development of T-lymphomas in AKR/J mice.
Chan LN; Zhang S; Cloyd M; Chan TS
Anticancer Res; 1997; 17(1A):499-503. PubMed ID: 9066702
[TBL] [Abstract][Full Text] [Related]
14. Retinoid metabolism in the prostate: effects of administration of the synthetic retinoid N-(4-hydroxyphenyl)retinamide.
Lewis KC; Hochadel JF
Cancer Res; 1999 Dec; 59(23):5947-55. PubMed ID: 10606240
[TBL] [Abstract][Full Text] [Related]
15. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
Gupta S; Ahmad N; Marengo SR; MacLennan GT; Greenberg NM; Mukhtar H
Cancer Res; 2000 Sep; 60(18):5125-33. PubMed ID: 11016639
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.
Xu H; Cheepala S; McCauley E; Coombes K; Xiao L; Fischer SM; Clifford JL
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):969-79. PubMed ID: 16467112
[TBL] [Abstract][Full Text] [Related]
17. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
Torrisi R; Pensa F; Orengo MA; Catsafados E; Ponzani P; Boccardo F; Costa A; Decensi A
Cancer Res; 1993 Oct; 53(20):4769-71. PubMed ID: 8402658
[TBL] [Abstract][Full Text] [Related]
18. Dietary agents in the chemoprevention of prostate cancer.
Shukla S; Gupta S
Nutr Cancer; 2005; 53(1):18-32. PubMed ID: 16351503
[TBL] [Abstract][Full Text] [Related]
19. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
20. Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft.
Singh RP; Deep G; Blouin MJ; Pollak MN; Agarwal R
Carcinogenesis; 2007 Dec; 28(12):2567-74. PubMed ID: 17916909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
